Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic HER2-Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT05135104
What this trial is testing

Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period

Who this might be right for
Metastatic Breast Cancer
Asociatia Oncohelp - Centrul de Oncologie Oncohelp 650
Not applicableEnded earlyNCT05068726
What this trial is testing

Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

Who this might be right for
Metastatic Breast Cancer
GE Healthcare 51
Testing effectiveness (Phase 2)UnknownNCT04669587
What this trial is testing

ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)

Who this might be right for
Estrogen Receptor-PositiveHER2-NegativeLocally Advanced Breast Cancer+1 more
EnhancedBio USA Inc. 106
Testing effectiveness (Phase 2)Ended earlyNCT02202746
What this trial is testing

Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerMBC+5 more
Clovis Oncology, Inc. 178
Testing effectiveness (Phase 2)Ended earlyNCT06851442
What this trial is testing

Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 8
Large-scale testing (Phase 3)Study completedNCT00820222
What this trial is testing

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

Who this might be right for
Metastases, Brain
Novartis Pharmaceuticals 540
Testing effectiveness (Phase 2)Study completedNCT00337649
What this trial is testing

Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 27
Testing effectiveness (Phase 2)Study completedNCT00036868
What this trial is testing

Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC 90
Large-scale testing (Phase 3)Active Not RecruitingNCT06018337
What this trial is testing

DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Who this might be right for
Metastatic Breast Cancer
DualityBio Inc. 541
Testing effectiveness (Phase 2)Looking for participantsNCT04683679
What this trial is testing

Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerBreast Cancer+1 more
Memorial Sloan Kettering Cancer Center 34
Large-scale testing (Phase 3)Study completedNCT01740427
What this trial is testing

Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

Who this might be right for
Breast Neoplasms
Pfizer 666
Testing effectiveness (Phase 2)Looking for participantsNCT06525766
What this trial is testing

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen-receptor-positive Breast CancerMetastatic HER2-Negative Breast Carcinoma+1 more
Mayo Clinic 35
Testing effectiveness (Phase 2)UnknownNCT05927779
What this trial is testing

Study of TFX06 in Women With Advanced Breast Cancer.

Who this might be right for
ER+, HER2- Advanced Breast CancerMetastatic Breast Cancer
Zhejiang Yangli Pharmaceutical Technology Co., Ltd. 74
Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Early research (Phase 1)Study completedNCT01245205
What this trial is testing

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+4 more
National Cancer Institute (NCI) 28
Large-scale testing (Phase 3)Study completedNCT01026142
What this trial is testing

A Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 452
Large-scale testing (Phase 3)Not Yet RecruitingNCT07406542
What this trial is testing

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Who this might be right for
Recurrent or Metastatic Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd. 400
Testing effectiveness (Phase 2)Study completedNCT00146042
What this trial is testing

UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer

Who this might be right for
HER-2 Positive Metastatic Breast Cancer
University of Michigan Rogel Cancer Center 22
Early research (Phase 1)Study completedNCT02649686
What this trial is testing

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

Who this might be right for
Metastatic Breast Cancer
Canadian Cancer Trials Group 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT05721248
What this trial is testing

STOP-HER2: Stopping Trastuzumab in HER2+ MBC

Who this might be right for
Breast CancerMetastatic Breast CancerHER2-positive Breast Cancer
Dana-Farber Cancer Institute 82
Next Page